Oxford Biomedica to Present at 41^st Annual J.P Morgan Healthcare Conference

Oxford, UK - 21 December 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that Stuart Paynter, Chief Financial Officer, will present at the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, 11 January 2023 at  4.30pm PT. The presentation will be available on the Oxford Biomedica website after the conference at www.oxb.com/investors/results-reports-presentations-webcasts.

-Ends-

Enquiries:       

Oxford Biomedica plc:

Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783 000

Taylor Boyd, VP, Head of IR - T: +1 919 539 1234

Sophia Bolhassan, VP, Head of Corporate Affairs - T: +44 (0)7394 562 425

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

Mary-Jane Elliott / Matthew Cole            / Angela Gray

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Further information is available at www.oxb.com.